InvestorsHub Logo

ralphey

05/04/21 9:21 PM

#338535 RE: Pharmacydude #338532

PD with the coupons V is cheaper than gV - so if its all about price the patient would be choosing V over gV but they are not provided with that choice and therein lies the infringement

iryokabu

05/04/21 9:23 PM

#338536 RE: Pharmacydude #338532

PD,

The only thing that saves Amarin is successful COVID data from PREPARE-IT.



I disagree with you. The only thing that saves Amarin is API supply. One day Vascepa will be successful regardless of COVID trials.

Gbert

05/05/21 5:54 AM

#338584 RE: Pharmacydude #338532

I wonder how many scripts had the “Reduce it” indication on them and were still substituted? If HN offered gV in that situation would you agree on infringement?

There should be a PA process to get gV since it represents a much smaller market for use and hence its approval. If the use is for MACE reduction in a CV patient - gV is not covered.